CRL was bought for their capability manually manufacture. No way NWBO needs to sell or license their machines to companies to create competing products in dendritic cell vaccines. I completely differ with you on this and this is a drug company, not an OEM for medical products. you keep trying to turn them into an equipment manufacturing and licensing company, and that is a terrible business model and it would make the last 2 decades and investment a total waste of time since selling such equipment doesn’t require the same kind of clinical trials or proof to drug regulators that creating a drug/biological treatment and vaccine requires.
That would be an easily copied and low margin business with high capital costs.
I own NWBO. My posts on iHub are always posted expressly as just my humble opinion (IMHO) and none are advice, just my opinion. I am NOT a financial advisor, and it is assumed that everyone is responsible for their own due diligence.
